Member Info for Doc83

Peer, not peed:D

Would the world want this peed reviewed sooner though, given that we would be proposing selling it asap?

Top line before peer review though? So would suggest they do not intend for this to go into March?

Any of the more erudite members able to confirm if this is worth reading into, or are they just estimated dates from when the trial was first set up?

All the big buys not doing much for the SP. :/

Ndn71, I do tend to agree with a lot of that.

Another positive for me at least is that they will have at least completed the Omicron IV tests by now? If so, had they been negative they would have had to RNS that as it destroys the whole story of it being broad spectrum.

If it goes into March, I’ll agree the delay would be worrying.

Thanks Matml74.

Which company… Catalent?

HSD - the RNS from December said they would publish top line 35 day data first. The long Covid 90 day data might take quite a while to analyse and we'd potentially be into April/May for that. Because of that, I'm sure the 90 day outcome will come separately.

Oakleaf - is the information on the web or in the public domain? If so, you should be ok to let us know where it is and would be much appreciated.

Catalent do have a "Director - Innovation Oral & Specialty Delivery" role available... ;)

Come on then Oak, spill the beans!

Manifesto, if there is a buyer then they are adding at a snails pace. Hardly any volume today and plenty of shares available to buy on the order book at the current price.

Oakleaf, you tease! Is this just some fun or something real that I should set my mind to and find?!

Gunto, ref ACTIV-2 phase 3 not starting yet, do you think this is simply because of the problems with the comparator drugs. Or could it be something more positive, like they have been able to view the SPRINTER data and see no need to run their own trial, despite it being in the home setting vs hospital?

I would have thought they would still want to do the trial, but it seems strange to have such delays when time is of the essence.

More great finds from gggg.

The Tweet from Lawrence Tabak, NIH Director, references research carried. For those interested, it looks like the research carried out by Rockefeller University and presented by them in the video below, which Oakleaf / PMJH posted yesterday. Well worth a watch:

https://www.youtube.com/watch?v=nX_sYidwJ6w

RICH3R - Certainly no FOMO just yet. Charts as flat as a fart and volume almost non existent.

Plenty of shares on the offer so no shortage of stock.

My understanding on Activ was that it was going to be late 2022?

I was one of the January brigade that mistakenly thought we might get results in January. However, that was probably more hope. From Monday onwards, that hope turns to expectation. This is close. Very close. If not Monday then a matter of days, not weeks IMO.

I'm still amazed this is 190p. Even for those who just punt stocks, hoping to time it right and make a quick and large return, where are they? Sometimes I forget that 99.99999% of the world have never heard of Synairgen. We are hopefully the lucky few who have.

Sceptik, if war really did break out then there are no hiding places in the stock market. But utilities, pharma etc are typically more defensive.

HPHQ - they are indeed. If it’s not the coming Monday, it’ll be one of those. I don’t see this going into March. For one, I do not consider that “early 2022” and as Elsol has commented, so much news is now coming out that they will need to make an RNS soon.

Monday it is!

RM said in the presentation below that “companies with blockbuster drugs sell out for £4-8bn” or something in that order and that “we are looking to provoke some sort of event like this”.

https://m.youtube.com/watch?v=BzK7lCjN6Jw